Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe by Le Rhun, Emilie et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Diagnosis and treatment patterns for patients with leptomeningeal
metastasis from solid tumors across Europe
Le Rhun, Emilie; Rudà, Roberta; Devos, Patrick; Hoang-Xuan, Khê; Brandsma, Dieta; Pérez Segura,
Pedro; Soffietti, Riccardo; Weller, Michael
Abstract: Leptomeningeal metastases are a late manifestation of systemic cancer which affects up to 10%
of patients with solid tumors. Prognosis is poor, and overall survival at 1 year is only approximately
10%. Management depends mainly on general and neurological condition, primary tumor, and patterns
of metastasis, notably absence or presence of concurrent systemic or solid brain metastases. Here we set
out to characterize current practice patterns of diagnosis and treatment of patients with leptomeningeal
metastasis in Europe. We prepared a web-based survey including 25 simple or multiple choices questions
on best practice supplemented by eight case vignettes with various diagnosis and management options.
The survey was sent to the membership of the European Association of Neuro-Oncology and the European
Organisation for Research and Treatment of Cancer Brain Tumor Group. Between April 7, 2016 and
August 8, 2016, 224 colleagues from 26 countries initiated the survey, 115 colleagues completed the
whole survey. There were major differences both in the general diagnostic and therapeutic approach,
e.g., regarding the use of cerebrospinal fluid (CSF) flow studies, intra-CSF chemotherapy, various types
of radiotherapy, and even more so when selecting decisions on diagnostic and therapeutic measures for
single case vignettes. Diagnosis and treatment decisions for patients with leptomeningeal metastasis
from solid tumors vary widely across Europe. Standardization of diagnosis and evaluation tools as well
as controlled studies to improve the level of evidence for all therapeutic approaches to LM are required.
DOI: https://doi.org/10.1007/s11060-017-2452-6
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-141051
Journal Article
Accepted Version
Originally published at:
Le Rhun, Emilie; Rudà, Roberta; Devos, Patrick; Hoang-Xuan, Khê; Brandsma, Dieta; Pérez Segura,
Pedro; Soffietti, Riccardo; Weller, Michael (2017). Diagnosis and treatment patterns for patients with
leptomeningeal metastasis from solid tumors across Europe. Journal of Neuro-Oncology, 133(2):419-427.
DOI: https://doi.org/10.1007/s11060-017-2452-6
 1 
Diagnosis and treatment patterns for patients with leptomeningeal metastasis 
from solid tumors across Europe 
 
Emilie Le Rhun1,2, Roberta Rudà3, Patrick Devos4, Khê Hoang-Xuan5, Dieta Brandsma6, 
Pedro Pérez Segura7, Riccardo Soffietti3, Michael Weller2 
 
1Lille University, Inserm U1191 PRISM, Villeneuve d’Ascq, France; Neuro-oncology, Department of 
Neurosurgery, University Hospital, Lille, France; Breast unit, Department of Medical Oncology, Oscar 
Lambret Center, Lille, France 
2Department of Neurology, University Hospital and University of Zurich, Clinical Neuroscience Center, 
Zurich, Switzerland  
3Department of Neuro-Oncology, City of Health and Science and University of Turin, Italy  
4Lille University, CHU Lille, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000 Lille, 
France  
5 Department of Neuro-Oncology Marazin, Pitie-Salpetriere Hospital and University Pierre et Marie Curie, 
Paris VI, Paris, France, on behalf of the Association de Neuro-Oncologie d’Expression Française 
(ANOCEF) 
6 Department of Neuro-Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, 
The Netherlands, on behalf of the Dutch Neuro-Oncology Group 
7 Medical Oncology Department, Hospital Clínico San Carlos (Madrid-Spain), on behalf of Spanish Group 
of Investigation in Neurooncology (GEINO) 
 
Running title: Leptomeningeal metastasis in Europe 
 
Corresponding author: Emilie Le Rhun, Neuro-oncology, Department of Neurosurgery, 
Rue Emile Laine, University Hospital – CHRU, 59037 Lille cedex, France  
tel: +33.3.20.44.65.42, fax: +33.3.20.44.68.08, email: emilie.lerhun@chru-lille.fr  
 
 2 
Funding: none. 
 
Manuscript word count: abstract: 243, text: 2911, references: 35, tables: 1, figures: 1, 
supplementary note case vignettes:1, supplementary tables: 1, supplementary figures: 1 
 
 3 
Abstract  
Background: Leptomeningeal metastases are a late manifestation of systemic cancer 
which affects up to 10% of patients with solid tumors. Prognosis is poor, and overall 
survival at one year is only approximately 10%. Management depends mainly on 
general and neurological condition, primary tumor, and patterns of metastasis, notably 
absence or presence of concurrent systemic or solid brain metastases. Here we set out 
to characterize current practice patterns of diagnosis and treatment of patients with 
leptomeningeal metastasis in Europe. 
Methods: We prepared a web-based survey including 25 simple or multiple choices 
questions on best practice supplemented by 8 case vignettes with various diagnosis 
and management options. The survey was sent to the membership of the European 
Association of Neuro-Oncology (EANO) and the European Organisation for Research 
and Treatment of Cancer (EORTC) Brain Tumor Group. 
Results: Between April 7, 2016 and August 8, 2016, 224 colleagues from 26 countries 
initiated the survey, 115 colleagues completed the whole survey. There were major 
differences both in the general diagnostic and therapeutic approach, e.g., regarding the 
use of cerebrospinal fluid (CSF) flow studies, intra-CSF chemotherapy, various types of 
radiotherapy, and even more so when selecting decisions on diagnostic and therapeutic 
measures for single case vignettes.  
Discussion: Diagnosis and treatment decisions for patients with leptomeningeal 
metastasis from solid tumors vary widely across Europe. Standardization of diagnosis 
and evaluation tools as well as controlled studies to improve the level of evidence for all 
therapeutic approaches to LM are required. 
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Importance of the study  
Leptomeningeal metastasis is typically a late and life-threatening complication from 
solid cancers. Diagnosis and management pathways are poorly standardized because 
of heterogeneous pretreatment and clinical presentation and because of a lack of data 
from randomized trials. In an effort to define the most important areas of consent versus 
dissent among neuro-oncologists in Europe, we performed a questionnaire-based 
survey to explore current standards of practice. The survey allowed to identify several 
areas of clinical research where more solid data are urgently needed to derive 
evidence-based guidelines for diagnosis and treatment: (i) the role of systemic 
pharmacotherapy in patients with isolated central nervous system disease, (ii) selection 
of patients for intra-CSF therapy and (iii) the integration of radiotherapy into multimodal 
treatment approaches. 
 
Text  
Introduction  
 Leptomeningeal metastasis is a serious complication of systemic cancer 
commonly occurring in later disease stages which affects approximately 10% of patients 
with solid tumors. The risk is highest for patients with breast cancer, lung cancer and 
melanoma. Survival at one year is in the range of approximately 10% and varies 
profoundly by primary tumor. Clinical evaluation, magnetic resonance imaging (MRI) 
and cerebrospinal fluid (CSF) analysis are the most important diagnostic measures [1]. 
Treatment recommendations vary mainly by primary tumor and pattern of brain and 
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meningeal disease, that is, e.g., the absence or presence of concurrent systemic or 
solid brain metastasis, the radiological presentation, and the absence or presence of 
tumor cells in the cerebrospinal fluid (CSF), and are typically rather individualized [2]. 
Many important questions regarding diagnosis and treatment of LM remain controversial 
and have never been explored in controlled clinical trials. Heterogeneous patterns of 
presentation, divergent modes of commonly heavy pretreatment, and poor prognosis 
are the main reasons why it has remained challenging to conduct prospective clinical 
trials in this patient population. Here we designed a questionnaire-based survey to 
explore the current routine clinical practice of diagnosing and treating LM and to identify 
the most important controversies to be addressed in future clinical trials across Europe. 
 
Methods 
 A web-based survey containing 25 general questions on current practice patterns 
as well as 8 case presentations with diagnosis and management questions 
(Supplementary Note) was sent to members of the European Association of Neuro-
Oncology (EANO) and of the Brain Tumor Group of the European Organisation for 
Research and Treatment of Cancer (EORTC) in April 2016 via the respective email 
listings of these organizations. The case vignettes are real patients from the authors` 
clinical practice and were selected based on their representation of primary cancers and 
the typical challenges associated with the diagnosis and treatment of LM from solid 
cancers. Responses were analysed with a focus on age and discipline of participants, 
physician in charge of LM at the center, and the number of LM patients seen per month. 
Comparisons between groups were done using Chi-square or Fisher exact test. 
Statistical analyses were performed with SAS Software, V9.4 (Cary, NC). 
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Results 
 
General information 
 Between April 7, 2016 and August 8, 2016, a total of 224 colleagues from 26 
countries initiated the survey and 115 colleagues completed the whole survey. Fifteen 
colleagues only opened the file without answering any of the questions. Rates of “no 
response” for the general questions varied between 8.5% and 15% with the exception 
on the question addressing the route of administration of intra-CSF therapy to which 
23% of participants did not answer (Table).  
 Participants came mainly from France (n=35, 15.5%), Italy (n=28, 12.5%), 
Netherlands (n=22, 10%) and Spain (n=19, 8.5%) (Figure A), and the leading disciplines 
were neurology (n=77, 34%), medical oncology (n=52, 23%), radiation oncology (n=42, 
19%) and neurosurgery (n=23, 10%) (Figure B). The age distribution was as follows: 
31-40 years (n=56, 25%), 41-50 (n=69, 31%), 51-65 (n=76, 34%) (Supplementary 
Figure 1). Three colleagues each were 30 years or younger, or older than 65; 17 
participants did not indicate their age. Hundred-nineteen participants (53%) indicated to 
see not more than 1 LM patient per month, 78 participants (35%) indicated to see 2-4 
patients per month, and only 9 participants (4%) indicated to see 5 patients per month 
or more (Supplementary Figure 2). Almost no differences were observed between 
physicians in charge of 0-1 LM patients per month and physicians in charge of at least 2 
patients per month among the different items of the survey. 
 One hundred-twenty nine participants (58%) felt that they were the neuro-
oncologist in charge of LM at their institution (Supplementary Figure 3). Medical 
oncologists (54.5%) or neurologists (48%) were most often reported to be responsible 
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for the diagnosis of LM, whereas medical oncologists (63%) were more often in charge 
of treatment than neurologists (32%) or radiation oncologists (11%) (Figure C).  
 
Diagnosis of LM 
 Only 36 participants (16%) indicated that a neurological scale was used to score 
the results of the neurological examination (Table). No difference was observed 
between neurologists and participants from other specialties (Supplementary Table). 
Only 51 colleagues (23%) reported that cerebrospinal MRI was not always done in 
patients with suspected LM. Similarly, only 64 participants (28.5%) reported that CSF 
flow studies were never done in the diagnostic work-up. However, a CSF flow study was 
reported to be always performed at LM diagnosis by significantly more participants not 
in charge of LM (24.5%) than by participants in charge of LM (13%) (p=0.043).  
Only 125 participants (56%) indicated that CSF analysis was always performed as part 
of the diagnostic work-up in case of suspected LM from solid tumors whereas 78 
participants (35%) indicated that CSF analysis was only done in case of doubt after 
clinical and MRI evaluation (Table). These numbers were much lower for suspected LM 
from gliomas, 39 participants (17.5%) versus 40 participants (18%). Radiation 
oncologists declared less often always performing a CSF cytology in case of suspicion 
of LM from solid tumors (26%) than neurologists (61%), medical oncologists (79%) or 
neurosurgeons (61%) (p<0.0001). On the contrary, CSF analysis was indicated in case 
of doubt after clinical and MRI evaluation for LM from solid tumors mainly according to 
radiation oncologists (<0.0001). Radiation oncologists also declared less frequently to 
perform CSF analysis (5%) in case of suspected LM from gliomas than other specialists 
(neurologists: 17%, medical oncologists: 23%, neurosurgeons: 17%) (p=0.044). The 
indication for CSF analysis for the diagnosis of LM varied significantly also by age. 
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Participants between 31-40 and 51-65 years declared more often than participants 
between 41-50 years to always perform CSF cytological analysis in case of suspicion of 
LM from solid tumors or from gliomas (p=0.0002, p=0.0015) (Supplementary Table).  
 More than half (56.5%) of participants reported that CSF was processed within 
one hour. Interestingly, similar numbers of participants felt that a CSF cytology defined 
as atypical should be considered negative (40.5%) or positive (44.5%). In contrast, a 
CSF cytology defined as suspicious was considered positive by 167 participants 
(74.5%). Only 21 participants (9%) felt that a positive cytology was always required to 
diagnose LM (Table).  
 
Treatment 
The decision for systemic treatment was based on the primary cancer according to 126 
participants (56%), but on CSF and MRI findings according to only 66 participants 
(29.5%), although multiple answers were allowed. Systemic treatment was declared 
being always administered when feasible by only 71 participants (31.5%) (Table). 
Systemic treatment was always recommended when feasible by medical oncologists in 
50% and by neurosurgeons in 48%, as opposed to only 26% of radiation oncologists 
and 22% of neurologists (p=0.0029). The role of the primary tumor for systemic 
treatment was judged similar across disciplines (Supplementary Table). 
 The decision for intra-CSF treatment was again most often based on the primary 
cancer (n=126, 56%) but also on CSF and MRI findings (n=81, 36%) and depending on 
systemic treatment (n=68, 30.5%). Intra-CSF treatment was declared as being never 
administered by only 23 participants (10.5%) (Table). The indication for intra-CSF was 
determined by CSF and MRI characteristics for 47% of neurologists and 42% of medical 
oncologists, but only 30.5% of neurosurgeons and 21.5% of radiation oncologists 
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(p=0.039) (Supplementary Table). Almost half of the participants (103, 46%) selected 
intraventricular intra-CSF chemotherapy over intralumbar therapy only if repeated 
lumbar punctures were not feasible whereas 50 participants (22.5%) generally preferred 
intraventricular chemotherapy. Intraventricular intra-CSF chemotherapy was preferred 
over intralumbar administration for most patients by 31% of the participants in charge of 
LM versus only 12% of participants not in charge of LM (p=0.0025) (Table). No 
significant difference was observed between participants according to their specialties 
regarding the route of administration of intra-CSF chemotherapy (Supplementary 
Table). 
Only 35 participants (15.5%) felt that WBRT should always be performed. WBRT was 
always recommended by 35% of neurosurgeons and 28.5% of radiation oncologists, but 
by only 14.5% of neurologists and 4% of medical oncologists (p=0.0012). WBRT was 
proposed in case of multifocal nodular disease by 73% of medical oncologists, 56% of 
neurologists, 50% of radiation oncologists and 39% of neurosurgeons (p=0.0248) 
(Supplementary Table). 
Most participants (n=164, 73%) declared performing focal radiotherapy in LM patients in 
case of neurological symptoms only when these could be linked to MRI abnormalities. 
Only 30 participants (13.5%) agreed to opt for focal RT based on neurological 
symptoms only in LM patients (Table). Focal radiotherapy based on neurological 
symptoms in the presence of MRI abnormalities only was proposed mainly by radiation 
oncologists (90.5%) and medical oncologists (86.5%) as compared to neurologists 
(71.5%) and neurosurgeons (74%) (p=0.0401) (Supplementary Table).  
Cerebrospinal MRI for follow-up was reported to be done routinely by 108 participants 
(48%), commonly done in 2 to 3 months intervals (60.5%) (Table). Standardized MRI 
follow-up was done more often when participants were in charge of LM (0.0406), 
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whereas 25.5% of participants in charge of LM and 45% of participants not in charge 
planned MRI only depending on clinical course. No significant difference was observed 
among participants from different specialties regarding the imaging follow-up. To define 
the response status, 120 participants (53.5%) reported that they considered changes in 
steroid dose. Change of steroids dose was considered as part of criteria for response 
assessment of LM by 81% of medical oncologists, 62.5% of radiation oncologists, 
56.5% of neurosurgeons and 50.5% of neurologists (p=0.0071) (Supplementary Table). 
 
Case vignettes 
 Eight cases were proposed to explore the diagnosis and treatment strategies in 
distinct situations (Supplementary Note 1): non-small cell lung cancer (NSCLC), 
epidermal growth factor receptor (EGFR) wildtype (case 1) and EGFR mutated (case 5); 
melanoma, BRAF mutated (case 2); breast cancer, HER2-negative (case 3) and HER2-
positive (case 4); medulloblastoma (case 6); glioblastoma (case 7) and ependymoma 
(case 8). The completion rate was lower than for the general questionnaire with the 
following percentages of “no response”: case 1: 37.5%; case 2: 40-47.5%; case 3: 46-
61%; case 4: 48-50.5%; case 5: 55-66%; case 6: 59%-64.5%, case 7: 57-60.5% and 
case 8: 55.5-60%). The highest rates of non-response within each case were observed 
when participants had to select a systemic agent. 
 Cases 2 and 5 addressed the initial evaluation of LM. Most participants agreed 
on the role of completing the initial evaluation of LM with an entire spinal MRI when 
lesions were first diagnosed in the brain. Only a minority of participants performed CSF 
flow studies at diagnosis. For most cases, no clear consensus was observed for 
treatment recommendations. However, most participants agreed on the value of 
combining therapeutic options. WBRT was recommended most of the time in 
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combination with systemic treatment and/ or intra-CSF in case of diffuse linear cerebral 
involvement (cases 2 and 3). However, WBRT was not recommended in the absence of 
brain involvement on cerebral MRI (case 4). Systemic treatment was widely proposed in 
almost all cases, with the exception of ependymoma (case 8), but without consensus on 
the choice of agent (cases 2, 5, 6, 8), with the exception of capecitabine for LM from 
breast cancer LM (case 3) and of a nitrosourea for LM from glioblastoma (case 7). Half 
of the participants recommended intra-CSF chemotherapy in non-brain primary tumors 
with LM, but almost no intra-CSF therapy was suggested for LM from medulloblastoma 
(case 6), glioblastoma (case 7) or ependymoma (case 8). Intra-CSF chemotherapy was 
mostly recommended in the presence of tumor cells in the CSF, but also when CSF 
cytology was negative (case 1). Liposomal cytarabine and methotrexate were the 2 
intra-CSF drugs most commonly chosen. 
 
 
Discussion 
 
 The diagnosis of LM remains difficult and is defined in most recent cohorts by the 
presence of malignant cells in the CSF or, in the absence of malignant cells in the CSF, 
by concomitant characteristic clinical symptoms or signs and typical MRI findings [3-16]. 
However, clinical symptoms and signs vary according to areas of the CNS involved by 
tumor cells and may be difficult to distinguish from other neurological signs in cancer 
patients that are not related to LM.  
In this survey, we observed that only a minority (16%) of participants used a 
scale for the neurological evaluation, although recommended by the Response 
Assessment in Neuro-Oncology (RANO) – Leptomeningeal Metastasis (LM) group [1]. 
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We also noted that neurologists or medical oncologists do not use a neurological scale 
more frequently than neurosurgeons or radiation oncologists for the clinical evaluation. 
Such a scale could help defining the neurological signs related to LM and to detect 
changes in the neurological status during follow-up and should be considered for clinical 
practice.  
Surprisingly, 23% of the participants declared not to perform a cerebrospinal MRI 
in case of suspicion of LM, although LM may involve both brain and spine and although 
the radiological presentation should have an impact on the clinical decision making [2]. 
Moreover, not performing a complete baseline evaluation renders response assessment 
difficult. Sixty-four participants (28.5%) declared that an evaluation of CSF flow was 
never done at diagnosis. Mainly physicians who had declared not being in charge of LM 
in their respective hospitals proposed CSF flow studies. In most recent cohorts, 
including patients receiving intra-CSF chemotherapy, no CSF flow data are reported [3-
21] although recommended by the RANO-LM group for patients considered for intra-
CSF treatment [1].  
 Only half of the participants (56%) reported that CSF analysis was always done 
when LM from solid tumors except glioma is suspected, and up to 80% reported to 
perform CSF analyses only in case of doubt after clinical and MRI evaluation. Until now, 
despite a sensitivity rate of only 66-90% in recent cohorts of LM patients [4-9,15,22], the 
gold standard for the diagnosis of LM remains the demonstration of tumor cells in the 
CSF since clinical and MRI findings can be typical, but never specific. The prognostic 
role of malignant cells in the CSF at baseline and their role in the response assessment 
has not been clearly defined [1]. However, the identification of malignant cells in the 
CSF may influence the therapeutic decision, especially for intra-CSF treatment, which 
has a 1-2 mm limited penetration into tumoral nodules and acts probably mainly on 
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floating cells and linear contrast enhancement. Only 17.5% of participants declared to 
perform always a CSF analysis in case of suspicion of LM in glioma patients. This may 
be explained by the limited role of intra-CSF chemotherapy within the overall treatment 
strategy. 
 Radiation oncologists declared to perform less often systematic CSF analyses 
when LM is suspected. CSF volume and time between sampling and processing 
determine the quality of CSF samples and impact the sensitivity of CSF analysis 
[1,23,24,25]. When CSF analysis was performed, the median volume of CSF was 
declared as more than 5 ml by 55.5% of participants and between 2 and 5 ml by 30.5% 
of participants, and the median time between CSF sampling and processing was 
declared as less than 60 minutes in 56.5%, and in less than 90 minutes in 77.5%, which 
reflects broad acceptance of these recommendations.  
 Another important point concerns the interpretation of the results of CSF 
analyses. For 44.5% of participants, “atypical” CSF is usually considered as positive 
and for 74.5% of participants, “suspicious” CSF is considered as positive. In the RANO-
LM recommendations, an “atypical” CSF should be considered as negative and a 
“suspicious” CSF as positive [1]. These definitions have not been clearly defined by 
pathologists and have not been integrated into routine practice yet.  
 Several approaches can be combined for the treatment of LM. Systemic 
treatment is always administered by 31.5% of participants, and intra-CSF treatment is 
always given only by a minority or participants (3.5%). For others, decisions for 
systemic or intra-CSF treatment mainly depend on the primary cancer or on CSF and 
MRI findings. Intraventricular administration of chemotherapy was preferred over 
intralumbar administration for most patients only by 22.5% of participants whereas the 
majority reported to use a ventricular device only when lumbar punctures are not 
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feasible. No difference was observed for the route of administration of intra-CSF 
treatment according to the specialty of participants, but intraventricular route of 
administration was preferred by participants declared as being in charge of LM. This is 
probably because ventricular devices permit, through a rapid painless and safe 
procedure, a homogeneous distribution of the drug into the CSF [26,27,28].   
 WBRT was proposed for all LM cases by 15.5% of participants and most 
participants suggested WBRT in case of concomitant brain metastases or multifocal 
nodular disease. Importantly, participants declared to administer focal radiotherapy 
mainly when neurological symptoms were associated with MRI abnormalities and not 
for neurological symptoms or signs alone.  
 In this survey, treatment approach varied significantly according to specialty by 
training. Half of the medical oncologists recommended a systemic treatment approach 
whenever always when feasible versus a quarter of radiation oncologists. Moreover, a 
third of radiation oncologists always recommended WBRT versus less than 5% of 
medical oncologists.  
 Until now, only a few randomized trials in LM have been published, the last one 
more than 10 years ago [29-34]. Pretreatment evaluation, response assessment and 
the reporting of treatment-related toxicity varied widely in these studies [35]. Thus no 
strong recommendations can be established for the management of LM, and treatment 
options remain mainly based on expert opinion.  
 In this survey, only 48% of the participants declared performing a cerebrospinal 
MRI for the follow-up of their patients regularly, and in up to 28.5% only depending on 
the clinical course. More cerebrospinal MRI were recommended during the follow-up of 
patients by participants in charge of LM presumably because these colleagues 
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recognize the significance of the craniospinal extension of LM. No difference by 
specialty was observed for the frequency of MRI evaluation during follow-up. 
 Steroid doses were used as part of criteria to define the response to treatment as 
in brain metastases and gliomas for 53.5% of participants. The efficacy of steroids in the 
management of LM remains controversial, and the RANO-LM group proposed to not 
consider steroids in the response criteria for LM related to solid tumors [1]. 
 The optimal management of LM requires multidisciplinary care and diagnosis and 
treatment strategies should ideally be developed in tumor boards. Although we did not 
ask specifically for that, we suspect that LM patients are often no finally discussed in 
such boards because organ specialists for the most common primary tumors breast, 
lung and melanoma may not share tumor boards with the dedicated neuro-oncology 
teams. This is why individual physicians and their attitudes as explored here are very 
important.  
We are aware of several limitations of this study:  The number of participants was 
limited, 51% colleagues terminated after opening the survey, presumably because of 
the length of the survey. The poor response rate for some questions may also reflect 
uncertainties of many collegues and the, the lack of consensus for the management of 
the disease. That mainly physicians treating only one patient per month participated, 
may seem to challenge the validity of the results, but their responses did overall not 
differ from responses of colleagues who reported to see more patients. Since 
participants were not systematically approached, the validity of the answers still remains 
uncertain as the results represent what clinical report [36]. Finally, the survey focused 
on diagnosis and therapeutic options and missed the opportunity to explore the current 
practice of palliative care for LM patients. 
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 In conclusion, there are too few clinical trials data to derive evidence-based 
recommendations for diagnosis and treatment of LM from solid tumors. Nevertheless, 
this survey informs on addresses important topics for preparing institutional or national 
guidelines for the diagnosis and management of patients with LM from solid tumors and 
helps to identify areas of controversies which can be addressed in future clinical trials. 
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Figure legend 
 
Figure. Characteristics of participants. Distribution per country (A), per discipline (B) 
and per self-assessed role in the management of LM per discipline (C). In B, other 
disciplines indicated were: biologists (n=1, 0.5%), neuro-oncologists (n=3, 1%), 
neuropathologist (n=2, 1%); pediatric neurologist (n=2, 1%), radiologist (n=1, 0.5%). For 
C, there are no responses for diagnosis by 24 participants (11%) and for treatment by 
22 participants (10%). 
 
 
 
 
References  
1.  Chamberlain M, Junck L, Brandsma et al. Leptomeningeal Metastases: A RANO proposal 
for response criteria. Neuro Oncol. 2016 Dec 29. pii: now183. doi: 10.1093/neuonc/now183. 
 
2.  Le Rhun E, Galanis E (2016) Leptomeningeal metastases of solid cancer. Curr 
Opin Neurol 29:797–805. doi: 10.1097/WCO.0000000000000393 
3.  Regierer AC, Stroux A, Kühnhardt D, et al (2008) Contrast-Enhancing Meningeal 
Lesions Are Associated with Longer Survival in Breast Cancer-Related 
Leptomeningeal Metastasis. Breast Care Basel Switz 3:118–123. doi: 
10.1159/000121688 
4.  Gauthier H, Guilhaume MN, Bidard FC, et al (2010) Survival of breast cancer 
patients with meningeal carcinomatosis. Ann Oncol Off J Eur Soc Med Oncol 
ESMO 21:2183–2187. doi: 10.1093/annonc/mdq232 
5.  Lee S, Ahn HK, Park YH, et al (2011) Leptomeningeal metastases from breast 
cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer 
Res Treat 129:809–817. doi: 10.1007/s10549-011-1682-0 
6.  de Azevedo CRAS, Cruz MRS, Chinen LTD, et al (2011) Meningeal carcinomatosis 
in breast cancer: prognostic factors and outcome. J Neurooncol 104:565–572. doi: 
10.1007/s11060-010-0524-y 
7.  Yust-Katz S, Garciarena P, Liu D, et al (2013) Breast cancer and leptomeningeal 
disease (LMD): hormone receptor status influences time to development of LMD 
 19 
and survival from LMD diagnosis. J Neurooncol 114:229–235. doi: 
10.1007/s11060-013-1175-6 
8.  Le Rhun E, Taillibert S, Zairi F, et al (2013) A retrospective case series of 103 
consecutive patients with leptomeningeal metastasis and breast cancer. J 
Neurooncol 113:83–92. doi: 10.1007/s11060-013-1092-8 
9.  Abouharb S, Ensor J, Loghin ME, et al (2014) Leptomeningeal disease and breast 
cancer: the importance of tumor subtype. Breast Cancer Res Treat 146:477–486. 
doi: 10.1007/s10549-014-3054-z 
10.  Morris PG, Reiner AS, Szenberg OR, et al (2012) Leptomeningeal metastasis from 
non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J 
Thorac Oncol Off Publ Int Assoc Study Lung Cancer 7:382–385. doi: 
10.1097/JTO.0b013e3182398e4f 
11.  Umemura S, Tsubouchi K, Yoshioka H, et al (2012) Clinical outcome in patients 
with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung 
Cancer Study Group. Lung Cancer Amst Neth 77:134–139. doi: 
10.1016/j.lungcan.2012.03.002 
12.  Gwak H-S, Joo J, Kim S, et al (2013) Analysis of treatment outcomes of 
intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis 
from non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung 
Cancer 8:599–605. doi: 10.1097/JTO.0b013e318287c943 
13.  Riess JW, Nagpal S, Iv M, et al (2014) Prolonged survival of patients with non-
small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment 
era. Clin Lung Cancer 15:202–206. doi: 10.1016/j.cllc.2013.12.009 
14.  Kuiper JL, Hendriks LE, van der Wekken AJ, et al (2015) Treatment and survival of 
patients with EGFR-mutated non-small cell lung cancer and leptomeningeal 
metastasis: A retrospective cohort analysis. Lung Cancer Amst Neth 89:255–261. 
doi: 10.1016/j.lungcan.2015.05.023 
15.  Harstad L, Hess KR, Groves MD (2008) Prognostic factors and outcomes in 
patients with leptomeningeal melanomatosis. Neuro-Oncol 10:1010–1018. doi: 
10.1215/15228517-2008-062 
16.  Geukes Foppen MH, Brandsma D, Blank CU, et al (2016) Targeted treatment and 
immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol Off J 
Eur Soc Med Oncol ESMO 27:1138–1142. doi: 10.1093/annonc/mdw134 
17.  Rudnicka H, Niwińska A, Murawska M (2007) Breast cancer leptomeningeal 
metastasis--the role of multimodality treatment. J Neurooncol 84:57–62. doi: 
10.1007/s11060-007-9340-4 
18.  Niwińska A, Rudnicka H, Murawska M (2013) Breast cancer leptomeningeal 
metastasis: propensity of breast cancer subtypes for leptomeninges and the 
analysis of factors influencing survival. Med Oncol Northwood Lond Engl 30:408. 
doi: 10.1007/s12032-012-0408-4 
 20 
19.  Meattini I, Livi L, Saieva C, et al (2012) Prognostic factors and clinical features in 
patients with leptominengeal metastases from breast cancer: a single center 
experience. J Chemother Florence Italy 24:279–284. doi: 
10.1179/1973947812Y.0000000034 
20.  Lara-Medina F, Crismatt A, Villarreal-Garza C, et al (2012) Clinical features and 
prognostic factors in patients with carcinomatous meningitis secondary to breast 
cancer. Breast J 18:233–241. doi: 10.1111/j.1524-4741.2012.01228.x 
21.  Park JH, Kim YJ, Lee J-O, et al (2012) Clinical outcomes of leptomeningeal 
metastasis in patients with non-small cell lung cancer in the modern chemotherapy 
era. Lung Cancer Amst Neth 76:387–392. doi: 10.1016/j.lungcan.2011.11.022 
22.  Kwon J, Chie EK, Kim K, et al (2014) Impact of multimodality approach for patients 
with leptomeningeal metastases from solid tumors. J Korean Med Sci 29:1094–
1101. doi: 10.3346/jkms.2014.29.8.1094 
23.  Glantz MJ, Cole BF, Glantz LK, et al (1998) Cerebrospinal fluid cytology in patients 
with cancer: minimizing false-negative results. Cancer 82:733–739. 
24.  Rogers LR, Duchesneau PM, Nunez C, et al (1992) Comparison of cisternal and 
lumbar CSF examination in leptomeningeal metastasis. Neurology 42:1239–1241. 
25.  Dux R, Kindler-Röhrborn A, Annas M, et al (1994) A standardized protocol for flow 
cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci 121:74–
78. 
26.  Zairi F, Le Rhun E, Bertrand N, et al (2015) Complications related to the use of an 
intraventricular access device for the treatment of leptomeningeal metastases from 
solid tumor: a single centre experience in 112 patients. J Neurooncol. doi: 
10.1007/s11060-015-1842-x 
27.  Kennedy BC, Brown LT, Komotar RJ, McKhann GM (2016) Stereotactic catheter 
placement for Ommaya reservoirs. J Clin Neurosci Off J Neurosurg Soc Australas 
27:44–47. doi: 10.1016/j.jocn.2015.11.005 
28.  Morgenstern PF, Connors S, Reiner AS, Greenfield JP (2016) Image guidance for 
the placement of Ommaya reservoirs: A comparison of fluoroscopy and frameless 
stereotactic navigation in 145 patients. World Neurosurg. doi: 
10.1016/j.wneu.2016.04.090 
29.  Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of 
single-agent versus combination chemotherapy in meningeal carcinomatosis. J 
Clin Oncol Off J Am Soc Clin Oncol 5:1655–1662. 
30.  Grossman SA, Finkelstein DM, Ruckdeschel JC, et al (1993) Randomized 
prospective comparison of intraventricular methotrexate and thiotepa in patients 
with previously untreated neoplastic meningitis. Eastern Cooperative Oncology 
Group. J Clin Oncol Off J Am Soc Clin Oncol 11:561–569. 
31.  Glantz MJ, Jaeckle KA, Chamberlain MC, et al (1999) A randomized controlled trial 
comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal 
 21 
methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer 
Res Off J Am Assoc Cancer Res 5:3394–3402. 
32.  Boogerd W, van den Bent MJ, Koehler PJ, et al (2004) The relevance of 
intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a 
randomised study. Eur J Cancer Oxf Engl 1990 40:2726–2733. doi: 
10.1016/j.ejca.2004.08.012 
33.  Shapiro WR, Schmid M, Glantz M, Miller JJ (2006) A randomized phase III/IV study 
to determine benefit and safety of cytarabine liposome injection for treatment of 
neoplastic meningitis. ASCO Meet Abstr 24:1528. 
34.  Glantz MJ, LaFollette S, Jaeckle KA, et al (1999) Randomized trial of a slow-
release versus a standard formulation of cytarabine for the intrathecal treatment of 
lymphomatous meningitis. J Clin Oncol Off J Am Soc Clin Oncol 17:3110–3116. 
doi: 10.1200/jco.1999.17.10.3110 
35.  Chamberlain M, Soffietti R, Raizer J, et al (2014) Leptomeningeal metastasis: a 
Response Assessment in Neuro-Oncology critical review of endpoints and 
response criteria of published randomized clinical trials. Neuro-Oncol 16:1176–
1185. doi: 10.1093/neuonc/nou089 
36. Abrey LE, Louis DN, Paleologos N, Lassman AB, Raizer JJ, Mason W, Finlay J, 
Mac Donald DR, De Angelis LM, Cairncross JG; Oligodendroglioma Study Group. 
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-
Oncol 9(3):314-318. Epub 2007 Apr 13. 
 
 
 1 
 
Table. Responses to the general questions on current practice of diagnosing and treating LM  
DIAGNOSIS Number (% of participants) 
 
At your institution, a standardized 
neurological scale to score 
neurological symptoms/signs is 
performed for the management of 
LM? 
 
yes: 36 (16%) 
no: 165 (74% ) 
no response: 23 (10%) 
 
At your institution, a 
cerebrospinal MRI is always 
performed regardless of 
localizing neurologic symptoms / 
signs in suspected LM: 
 
yes: 153 (68%) 
no: 51 (23%) 
no response: 20 (9%) 
 
At your institution, a CSF flow 
study is performed for the 
diagnosis of LM from solid tumors 
other than gliomas:* 
 
always : 36 (16%) 
depending on patient’s characteristics: 62 (27.5%) 
depending on disease’s characteristics: 69 (31%) 
in case of toxicity of the intra-CSF treatment: 6 (2.5%) 
never: 64 (28.5%) 
no response: 21 (9.5%)  
 
At your institution, a CSF analysis 
is done (in cases without contra-
indication):* 
 
always in case of suspicion of LM from solid tumors other than glioma: 125 (56%) 
always in case of suspicion of LM from glioma (not other solid tumors): 39 (17.5%) 
only in case of doubt after clinical and MRI evaluation for solid tumors other than  glioma: 78 (35%) 
only in case of doubt after clinical and MRI evaluation for glioma: 40 (18%) 
no response: 19 (8.5%)  
 
At your institution, what is the 
median volume of CSF sample 
collected? 
 
0-2 ml: 3 (1.5%) 
2-5 ml: 68 (30.5%) 
5-10 ml: 86 (38%) 
>10 ml: 39 (17.5%) 
no response: 28 (12.5%) 
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At your institution, what is the 
median time between CSF 
sampling and processing? 
 
<30 minutes: 36 (16%) 
30-60 minutes: 91 (40.5%) 
60-90 minutes: 47 (21%) 
>90 minutes: 20 (9%) 
no response: 30 (13.5%) 
 
At your institution, a CSF 
cytology defined as «atypical» is 
usually considered: 
 
positive: 100 (44.5%) 
negative: 91 (40.5%) 
no response: 33 (15%) 
 
At your institution, a CSF 
cytology defined as «suspicious» 
is usually considered: 
 
positive: 167 (74.5%) 
negative: 28 (12.5%) 
no response: 29 (13%) 
 
At your institution, is positive CSF 
cytology is always required to 
diagnose LM? 
 
yes: 21 (9%) 
no: 181 (81%) 
no response: 22 (10%) 
 
In case of negative CSF cytology, 
a combination of clinical and 
radiological findings is considered 
sufficient to diagnose LM?  
 
yes: 191 (85%) 
no: 11 (5%) 
no response: 22 (10%) 
 
 
TREATMENT – FOLLOW UP 
 
Number (%) 
At your institution, systemic treatment 
for LM is administered:* 
 
always when feasible: 71 (31.5%)     
never: 2 (1%)        
depending on CSF and MRI findings: 66 (29.5%)    
depending on the primary cancer: 126 (56%)   
depending on molecular data of the primary cancer: 35 (15.5%) 
only in combination with intra-CSF treatment: 10 (4.5%) 
no response: 23 (10.5%)  
 
At your institution, intra-CSF treatment always: 8 (3.5%)        
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for LM is administered:* 
 
never: 23 (10.5%)         
depending on CSF and MRI findings: 81 (36%)    
depending on the primary cancer: 126 (56%)   
depending on molecular data of the primary cancer: 28 (12.5%)  
depending on the systemic treatment: 68 (30.5%) 
only in combination with a systemic treatment: 12 (5.5%) 
no response: 25 (10.5%) 
 
At your institution, intraventricular intra-
CSF chemotherapy is preferred over 
intralumbar intra-CSF chemotherapy:* 
 
for most patients: 50 (22.5%) 
only in patients with regular CSF flow studies: 15 (6.5%) 
only when no WBRT is given: 9 (4%) 
only if repeated lumbar punctures are not feasible: 103 (46%) 
only if patients require anticoagulation: 10 (4.5%) 
no response: 51 (23%) 
 
At your institution, WBRT is 
performed:* 
 
always: 35 (15.5%)                     
in case of concomitant BM only : 108 (48%)             
in case of nodular/bulky LM disease: 115 (51.5%)            
never: 4 (2%)  
no response: 27 (12%)   
 
At your institution, in a patient with a 
diagnosis of LM and a predominant 
symptomatic site (i.e. cauda equina, 
posterior fossa, skull base) you perform 
focal RT based on: 
 
neurological symptoms only: 30 (13.5%) 
neurological symptoms only when associated with MRI abnormalities: 164 (73%) 
no response: 30 (13.5%) 
 
At your institution, a cerebro-spinal MRI 
is always performed in the follow-up 
regardless of signs: 
 
yes: 108 (48%) 
no: 92 (41%) 
no response: 24 (11%) 
 
At your institution, what is the 
frequency of MRI examination in the 
follow-up? 
 
every 2 months: 30 (13.5%) 
every 2 months initially, then every 3 months: 54 (24%)  
every 3 months: 51 (23%)      
only depending on the clinical course: 64 (28.5%) 
no response: 25 (11%) 
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At your institution, the change of 
steroid doses following antineoplastic 
treatment is part of criteria for defining 
response or progression (as in brain 
metastases and malignant gliomas): 
 
yes: 120 (53.5%) 
no: 79 (35.5%) 
no response: 25 (11%) 
 
 
* multiple answers were allowed 
 
 
 1 
Case 1 NON-SMALL CELL LUNG CANCER, EGFR WILD TYPE 
59 year-old male at the time of neurological evaluation, coronaropathy and severe atheroma of 
cervical and femoral arteries 
• January 2012 : lung adenocarcinoma, EGFR negative, pT2b pN1 M0 
• February 2012 : lung + axillary resection followed by cisplatin + vinorelbine X 4 cycles 
• August 2015 : mediastinal lymph nodes progression  local radiotherapy, then 
carboplatin + paclitaxel 
• November 2015 : repeated falls leading to a brain MRI showing both brain and meningeal 
lesions. Spinal MRI: no CNS metastases. Normal neurological examination. Stable 
extracerebral disease 
 
Question 1 : if the CSF is negative, what would be your 
recommendation for the treatment of the patient ? 
Number (%) 
whole brain radiotherapy 42 (19%) 
whole brain radiotherapy followed by systemic treatment  64 (28.5%) 
whole brain radiotherapy followed by systemic treatment and intra-CSF 
chemotherapy 
15 (6.5%) 
stereotactic radiotherapy  3 (1.5%) 
stereotactic brain radiotherapy followed by systemic treatment  10 (4.5%) 
stereotactic brain radiotherapy followed by systemic treatment and intra-
CSF chemotherapy  
4 (2%) 
systemic treatment alone 2 (1%) 
systemic treatment and intra-CSF chemotherapy  6 (2.5%) 
intra-CSF chemotherapy alone  1 (0.5%) 
other 3 (1.5%) 
no answer 74 (33%)  
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Question 2 : if the CSF is positive, what would be your 
recommendation for the treatment of the patient ? 
Number (%) 
whole brain radiotherapy 24 (10.5%) 
whole brain radiotherapy followed by systemic treatment 42 (18.75%) 
whole brain radiotherapy followed by systemic treatment and intra-CSF 
chemotherapy 
43 (19%) 
stereotactic radiotherapy  2 (1%) 
stereotactic brain radiotherapy followed by systemic treatment  0 (0%) 
stereotactic brain radiotherapy followed by systemic treatment and intra-
CSF chemotherapy  
7 (3%) 
systemic treatment alone  4 (2%) 
systemic treatment and intra-CSF chemotherapy  8 (4%) 
intra-CSF chemotherapy alone 1 (0.5%) 
WBRT plus intra-CSF chemotherapy  2 (1%) 
other 16 (7%) 
no answer 75 (22.5%) 
 
Case 2 MELANOMA, BRAF-MUTATED 
38 year-old male at the time of neurological evaluation 
• May 2004 : nodular achromomatic dorsal melanoma, Clark IV, BRAF-mutated 
• June 2004 to April 2007 : inclusion in a clinical trial of vaccinotherapy with ganglioside 
• September 2007 : left axillary lymph node metastases, surgery (axillary resection) 
followed by radiotherapy 
• June 2011 : right axillary lymph node metastases, surgery (axillary resection) 
• May 2013 : lymph nodes, lung, spleen, liver metastases  inclusion in an anti-RAF/anti-
MEK clinical trial, vemurafenib arm, with a complete response 
• September 2014 : brain metastases  temozolomide 
• November 2014 : isolated progression of the brain metastases  dabrafenib 
• July 2015 : progression of one isolated brain metastasis  SRS by gammaknife, followed 
by dabrafenib + pembrolizumab 
• October 2015 : leptomeningeal lesions on brain MRI, with malignant cells in the CSF. 
Good general status (ECOG-PS=0), normal neurological examination. no systemic 
progression 
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Question 1 : how would you complete the initial evaluation ? 
Number (%) 
entire spinal MRI 
110 (49%) 
CSF flow study 
42 (17.75%) 
no more examination 18 (8%) 
other 
2 (1%) 
no answer 
90 (40%) 
  
Question 2 : which option would you recommend for the management of the patient ? 
  
whole brain radiotherapy     
whole brain radiotherapy followed by systemic treatment    
whole brain radiotherapy followed by systemic treatment and intra-CSF chemotherapy    
systemic treatment alone    
systemic treatment and intra-CSF chemotherapy    
intra-CSF chemotherapy alone    
whole brain radiotherapy plus intra-CSF chemotherapy    
other   
no answer    
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Question 3 : which systemic treatment would you choose ? 
Number (%) 
fotemustine  14 (6%) 
ipilimumab 19 (8.5%) 
dabrafenib + ipilimumab  21 (9.5%) 
nivolumab  38 (17%) 
other 26 (11.5%) 
no answer 106 (47.5%)  
Question 4 : Which agent would you use for intra-CSF chemotherapy? 
Number (%) 
liposomal cytarabine 36 (16%) 
methotrextate 32 (14.5%) 
thiotepa 5 (2%) 
I never use intra-CSF chemotherapy 39 (17.5%) 
other  10 (4%) 
no answer 102 (46%)   
Case 3 BREAST CANCER, HER2 NEGATIVE 
49 year-old at the time of neurological evaluation 
• 2002 : left invasive ductal carcinoma, ER-positive, PR-positive, HER2-negative 
• 2002 : surgery (mastectomy, axillary resection), chemotherapy (5-fluorouracil-epirubicine-
cyclophosphamide – FEC 50), hormonotherapy (tamoxifen) 
• 2005 : loco-regional recurrence  surgery, chemotherapy (3 FEC100, 3 docetaxel), 
radiotherapy, LH-RH analogue (triptoreline) 
• January 2007 : left axillary recurrence  capecitabine, surgery, axillary radiotherapy, 
triptoreline + arimidex 
• January 2008 : lymph nodes and pulmonary progression  paclitaxel + bevacizumab 
followed by maintenance bevacizumab and triptoreline 
• December 2009 : pulmonary progression  paclitaxel + bevacizumab followed by 
maintenance bevacizumab 
• January 2011 : pulmonary progression  paclitaxel + bevacizumab 
• September 2011 : severe neuropathy leading to an interruption of the treatment  
fulvestrant + triptoreline 
• September 2013 : local pulmonary progression  cyberknife + fulvestrant + triptoreline 
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• June 2014 : isolated cerebellar metastasis (no progression of the extracerebral disease), 
surgery, fossa posterior radiotherapy, fulvestrant + triptoreline 
• April 2015 : brain and spinal MRI with diffuse linear contrast enhancement ; neurological 
evaluation : mild reduction of visual acuity, left tinnitus, mild gait disorders, mild left lower 
limb deficit and numbness, urinary incontinence ; CSF analysis : presence of malignant 
cells. No progression of the extraCNS disease 
  
Question 1 : which option would you recommend for the management 
of the patient ? 
Number (%) 
whole brain radiotherapy 1 (0.5%) 
whole brain radiotherapy followed by systemic treatment 7 (3%) 
whole brain radiotherapy followed by systemic treatment and intra-CSF 
chemotherapy  3 (1.5%) 
whole brain radiotherapy and cauda equina radiotherapy followed by 
systemic treatment  26 (11.5%) 
whole brain radiotherapy and cauda equina radiotherapy followed by 
systemic treatment and intra-CSF chemotherapy 
14 (6.25%) 
cauda equina radiotherapy followed by systemic treatment 18 (8%) 
cauda equina radiotherapy followed by systemic treatment and intra-
CSF chemotherapy 
0 (0%) 
systemic treatment alone 6 (2.5%) 
systemic treatment and intra-CSF chemotherapy 22 (10%) 
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intra-CSF chemotherapy alone 18 (8%) 
other  6 (2.5%) 
no answer 103 (46%)  
Question 2 : which systemic treatment would you choose ? 
Number (%) 
capecitabine 33 (14.5%) 
paclitaxel 6 (2.5%) 
FEC 50 2 (1%) 
vinorelbine 14 (6.5%) 
gemcitabine 12 (5.5%) 
other  20 (9%) 
no answer 137 (61%)  
Question 3 : which intra-CSF agent would you use, if this therapeutic 
agent was available, and if leptomeningeal metastasis is confirmed: 
Number (%) 
liposomal cytarabine 38 (17%) 
methotrextate 43 (19%) 
thiotepa 2 (1%) 
I never use intra-CSF chemotherapy 16 (7%) 
other  7 (3%) 
no answer 118 (53%)  
Case 4 BREAST CANCER, HER2 POSITIVE 
62 year-old woman at the time of neurological evaluation. 
• 1996: right invasive ductal carcinoma (ER 9%, PR 31%) 
• 1996: surgery (mastectomy, axillary resection) and hormone therapy (aromatase 
inhibitors) 
• January 2015: slow onset of back pain and radicular pain L5-S1 on the right side, 
followed by weakness of legs and urinary incontinence over the next months 
• June 2015: spinal MRI with multiple nodular enhancing lesions from L1 to S1 in the 
leptomeninges (Fig. A); brain MRI: no abnormalities; CSF examination: neoplastic cells 
and modest protein content increase 
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• July 2015: Laminectomy with resection of the bulky lesion : histological confirmation of 
breast carcinoma (ER-negative, PR-negative, HER2 3+)  
 
  Fig. A       Fig. B  
Question 1 : what treatment would you choose if brain MRI is normal ? 
  
radiotherapy of the lumbar spine only   
systemic therapy (based on trastuzumab or another anti-HER2 agent)   
intrathecal chemotherapy only (either methotrexate or liposomal cytarabine)   
combination of lumbar radiotherapy and either systemic or intrathecal therapy   
combination of whole brain and lumbar radiotherapy and either systemic or intrathecal therapy   
whole brain radiotherapy and either systemic or intrathecal therapy   
other   
no answer    
• August – September 2015  radiotherapy to the whole spine (46 Gy, 23 fractions) 
followed by paclitaxel and trastuzumab 
• October 2015: reduction of the pain, frequency of urinary incontinence and weakness of 
legs; spinal MRI: no significant changes; brain MRI: no abnormalities; CSF examination: 
few inflammatory and atypical cells and protein content stable  
Question 2 : which option would you choose? 
Number (%) 
monitoring with MRI and CSF examinations 43 (19%) 
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prolongation of systemic chemotherapy 45 (20%) 
intrathecal chemotherapy (either methotrexate or liposomal cytarabine) 18 (8%) 
other  5 (2%) 
answer 113 (51%)  
• October 2015 – January 2016: intrathecal liposomal cytarabine (6 injections) 
• February 2016: neurologically stable; spinal MRI with mild reduction of enhancing lesions 
(Fig. B); brain MRI: no abnormalities; CSF examination: no atypical or neoplastic cells 
and normal protein content  
Question 3 : how would you judge the post-treatment MRI findings 
(Fig. B) in comparison with those of pre-treatment (post-surgery) MRI 
(Fig. A) ? 
Number (%) 
minor response (26-49% reduction of enhancing lesions) 35 (15.5%) 
partial response (50 or more % reduction of enhancing lesions)  49 (22%) 
non significant changes 15 (6.5%) 
too difficult for me to evaluate 14 (6.5%) 
no answer 111 (49.5%)  
Case 5 NON-SMALL CELL LUNG CANCER, EGFR-MUTATED 
49 year-old at the time of neurological evaluation 
• September 2012 : lung adenocarcinoma, TTF1 positive, EGFR positive (exon 19 
deletion), HER2 negative, KRAS negative, BRAF negative, with initially pleural extension 
(Tx N1 M1b) 
• September 2012 : gefitinib (6 months) followed by cisplatin + pemetrexed + 
gefinitib/placebo after a first lung progression (IMPRESS trial) 
• August 2013 : lung progression  docetaxel 
• January 2014 : brain and pleural progression  ifosfamide – gemcitabine X 9 
• October 2014 : suspicion of leptomeningeal metastases on brain MRI, stable extra-CNS 
disease. ECOG-PS= 0, but progressive headaches, fluctuant diploplia, mild gait disorder 
and mild cognitive disorder 
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Question 1 : how would you complete the neurological evaluation ? 
Number (%) 
entire spinal MRI 83 (37%) 
CSF analysis 74 (33%) 
CSF flow study 10 (4.5%) 
determination of the EGFR mutation in the CSF 28 (12.5%) 
no more examination 4 (2%) 
other 2 (1%) 
no answer 122 (54.4%)  
Question 2 : which option would you recommend for the management of the patient if leptomeningea        
cytology ? 
  
whole brain radiotherapy   
whole brain radiotherapy followed by systemic treatment    
whole brain radiotherapy followed by systemic treatment and intra-CSF chemotherapy   
stereotactic brain radiotherapy followed by systemic treatment   
stereotactic brain radiotherapy followed by systemic treatment and intra-CSF chemotherapy   
systemic treatment alone   
systemic treatment and intra-CSF chemotherapy   
intra-CSF chemotherapy alone   
other    
no answer   
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Question 3 : which systemic treatment would you choose if 
leptomeningeal metastasis was confirmed by positive CSF 
cytology ? 
Number (%) 
ifosfamide + gemcitabine 8 (3.5%) 
erlotinib 31 (14%) 
high-dose gefitinib  6 (2.5%) 
afatinib 19 (8.5%) 
other  12 (5.5%) 
no anwser 148 (66%) 
 
Question 4 : which intra-CSF treatment would you chose if 
leptomeningeal metastasis was confirmed by positive CSF 
cytology ? 
Number (%) 
liposomal cytarabine  33 (14.5%) 
methotrexate 24 (10.5%) 
thiotepa 5 (2%) 
I never use intra-CSF chemotherapy  23 (10%) 
other  7 (3%) 
no answer 132 (60%) 
 
 
Case 6 MEDULLOBLASTOMA 
22 year-old male 
• August 2010 : headache and vomiting  MRI: enhancing tumor in the cerebellum (Fig. A) 
• September 2010: Total resection of a medulloblastoma 
• October 2010 (at staging before radiotherapy): spine MRI with nodular enhancing lesions 
in the leptomeninges (Fig. B); brain MRI normal; CSF examination: no neoplastic cells 
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Fig. A 
 
  
Fig. B 
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Question 1 : what treatment would you choose? Number (%) 
standard whole CNS radiotherapy with boost to the spinal lesions 17 (7.5%) 
standard whole CNS radiotherapy followed by systemic chemotherapy  61 (27%) 
standard whole CNS radiotherapy followed by intrathecal chemotherapy 3 (1.5%) 
other  11 (5%) 
no answer 132 (59%) 
 
Question 2 : in case of systemic chemotherapy which drugs would 
you choose ? 
Number (%) 
cisplatin-based chemotherapy  62 (27.5%) 
high-dose chemotherapy 24 (10.5%) 
other  2 (1%) 
no answer 136 (61%) 
 
Question 3 : in case of intrathecal chemotherapy which agent 
would you choose ? 
Number (%) 
liposomal cytarabine 22 (10%) 
thiotepa 12 (5.5%) 
methotrexate 5 (2%) 
I never use intra-CSF treatment for medulloblastoma 37 (16.5%) 
other  3 (1.5%) 
no answer 145 (64.5%) 
 
• Following radiotherapy and intrathecal liposomal cytarabine the patient had a new MRI to 
evaluate the response (Fig. C) 
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Fig. C 
 
Question 4 : how would you judge the post-treatment MRI findings 
(Fig. C) in comparison with those of pretreatment MRI (Fig. B)? 
Number (%) 
minor response (26-49% reduction of enhancing lesions) 11 (5%) 
partial response (50 or more % reduction of enhancing lesions) 61 (27%) 
non-significant changes 1 (0.5%) 
too difficult for me to evaluate  15 (7%) 
no answer 136 (60.5%)  
Case 7 GLIOBLASTOMA 
23 year-old female 
• September 2013: partial complex seizures and headache → MRI: enhancing tumor in the 
thalamus and upper mesencephalon 
• October 2013: partial resection of a glioblastoma (IDH1/2 wild type and MGMT promoter 
unmethylated) 
• November – December 2013: EORTC-NCIC regimen (TMZ/RT → TMZ). 
• In late February 2014 : MRI with progressive local disease (Fig. A) and leptomeningeal 
enhancing lesions (Fig. B), with patient still ambulatory 
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Fig. A 
 
Fig. B 
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Question 1 : which would be your treatment of choice? Number (%) 
palliative care  5 (2%) 
systemic chemotherapy  53 (24%) 
intrathecal chemotherapy  3 (1.5%) 
radiotherapy of the spinal lesion 30 (13.5%) 
other 5 (2%) 
no answer 128 (57%) 
 
Question 2 : in case of systemic chemotherapy which drug would 
you choose? 
Number (%) 
nitrosourea (CCNU or fotemustine)  
60 (27%) 
bevacizumab  
18 (8%) 
dose-dense TMZ  
6 (2.5%) 
other   
4 (2%) 
no answer 
136 (60.5%)   
Case 8 EPENDYMOMA 
49 year-old female 
• February 2000: vertigo and gait ataxia → MRI: enhancing tumor in the fourth ventricle. 
• March 2000: subtotal resection of an ependymoma WHO grade II 
• April 2000: MRI: residual tumor in the IV ventricle; spinal MRI normal; CSF examination 
normal 
• April-May 2000 : radiotherapy on the posterior fossa (55 Gy) 
• June 2000: MRI with minor response 
• September 2000 – January 2009: MRI stable 
• October 2009: nodular enhancing lesions on the pons-IV ventricle (Fig. A) and along the 
spine (Fig. B), but patient neurologically asymptomatic and CSF negative 
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Fig. A 
 
 
Fig. B 
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 Question 1 : what do you recommend? Number (%) 
observation with MRI until neurological symptoms will develop  18 (8%) 
radiotherapy to the whole spine and cyberknife to the nodule in the pons  41 (18.5%) 
systemic chemotherapy  15 (6.5%) 
intrathecal chemotherapy  0 (0%) 
combination of focal radiotherapy and chemotherapy  26 (11.5%) 
no answer 124 (55.5%) 
 
Question 2 : if choosing chemotherapy which drug would you use?   
cisplatin/carboplatin  
  
temozolomide    
intrathecal liposomal cytarabine    
other    
no answer 
   
 
Supplementary Figure 1A : Repartition of physicians according to the age    
    
Supplementary Figure 1B : Repartition of physicians according to the number of 
patients with suspected LM seen per month  
    
Supplementary Figure 1C : Repartition of physicians according to being in charge or 
not of LM in their hospital  
 
Supplementary table: Response patterns by age, specialty, being in charge of LM at the center, or seeing 0-1 versus 2 or 
more patients per month 
 
 
Significant items p-values 
AGE 
 31-40 (n=54)  
(n, % of participants) 
41-50 (n=69) 
(n, % of participants) 
51-65 (n=78) 
(n, % of participants) 
 
Specialty by training 
(missing: 15) 
neurologist: 25 (47%) 
medical oncologist: 15 (28.5%) 
radiotherapist: 7 (13%) 
neurosurgeon: 6 (11.5%) 
neurologist: 20 (31%) 
medical oncologist: 14 (21.5%) 
radiotherapist: 24 (37%) 
neurosurgeon: 7 (11%) 
neurologist: 26 (38%) 
medical oncologist: 22 (32.5%) 
radiotherapist: 11 (16%) 
neurosurgeon: 9 (13%) 
0.0446 
Physician in charge of LM diagnosis: 
medical oncologist 
(missing data: 0) 
yes: 39 (72%) 
no: 15 (28%) 
yes: 35 (50.5%) 
no: 34 (49.5%) 
yes: 45 (57.5%) 
no: 33 (42.5%) 
0.0519 
Physician in charge of LM diagnosis: 
other 
(missing data: 0) 
yes: 1 (2%) 
no: 53 (98%) 
yes: 12 (17.5%) 
no:57 (82.5%) 
yes: 6 (7.5%) 
no: 72 (92.5%) 
0.0111 
Physician in charge of LM treatment: 
other 
(missing: 0) 
yes: 0 (0%) 
no: 54 (100%) 
yes: 9 (13%) 
no: 60 (87%) 
yes: 5 (6.4%) 
no: 73 (93.5%) 
0.0182 
CSF analysis performed: always for 
suspicion of LM from solid tumors 
except glioma 
(missing: 0) 
yes: 32 (59.5%) 
no: 22 (40.5%) 
yes: 31 (45%) 
no: 38 (55%) 
yes: 61 (78%) 
no: 17 (22%) 
0.0002 
CSF analysis performed: always for 
suspicion of LM from glioma 
(missing: 0) 
yes: 10 (18.%) 
no: 44 (81.5%) 
yes: 5 (7.25%) 
no: 64 (92.75%) 
yes:24 (31%) 
no: 54 (69%) 
0.0015 
CSF analysis performed only if doubt 
after clinical and MRI evaluation for a 
suspicion of LM from solid tumor 
(except glioma) 
(missing: 0) 
yes: 22 (40.5%) 
no: 32 (59%) 
yes: 34 (49%) 
no: 35 (71%) 
yes: 18 (23%) 
no: 60 (77%) 
0.0035 
a CSF cytology defined as “atypical” is 
considered as  
(missing: 15) 
positive: 33 (62.5%) 
negative: 20 (37.5%) 
positive: 32 (53.5%) 
negative: 28 (46.5%) 
positive: 31 (42.5%) 
negative: 42 (57.5%) 
0.0852 
intra-CSF treatment is always 
administered for LM 
(missing: 0) 
yes: 0 (0%) 
no: 54 (100%) 
yes: 2 (3%) 
no: 67 (97%) 
yes: 6 (7.5%) 
no: 72 (92.5%) 
0.0720 
intra-CSF treatment is never 
administered for LM 
(missing: 0) 
yes: 3 (5.5%) 
no: 51 (94.4%) 
yes: 1 (19%) 
no: 56 (81%) 
yes: 5 (6.5%) 
no: 73 (93.5%) 
0.0189 
intra-CSF treatment is administered for 
LM depending on CSF and MRI 
findings 
(missing: 0) 
yes: 29 (73.5%) 
no: 25 (46.5%) 
yes: 22 (32%) 
no: 47 (68%) 
yes: 30 (38.5%) 
no: 48 (61.5%) 
0.0457 
intraventricular CSF chemotherapy is 
preferred over lumbar intra-CSF 
therapy only in patients with regular 
CSF flow sudies 
(missing: 0) 
yes: 1 (2%) 
no: 53 (98%) 
yes:  9 (13%) 
no: 60 (87%) 
yes:  5 (6.5%) 
no: 73 (93.5%) 
0.0579 
whole brain radiation therapy is 
performed in case of concomitant brain 
metastases 
(missing: 0) 
yes: 6 (11%) 
no: 48 (89%) 
yes: 17 (24.5%) 
no: 52 (75.5%) 
yes: 11 (14%) 
no: 67 (85%) 
0.0972 
SPECIALTY BY TRAINING 
 neurologist (n=77) 
(n, % of participants) 
medical oncologist (n=52) 
(n, % of participants) 
radiotherapist (n=42) 
(n, % of participants) 
neurosurgeon (n=23) 
(n, % of participants) 
 
Physician in charge of LM at hospital 
(missing: 36) 
yes: 58 (79.5%) 
no: 15 (20.5%) 
yes: 31 (61%) 
no: 20 (39%) 
yes: 23 (55%) 
no: 19 (45%) 
yes: 11 (50%) 
no: 11 (50%) 
0.0104 
Physician in charge of the diagnosis of 
LM: medical oncologist 
(missing: 30) 
yes: 38 (49.5%) 
no: 39 (50.5%) 
yes: 45 (86.5%) 
no: 7 (13.5%) 
yes: 22 (52.5%) 
no: 20 (47.5%) 
yes: 12 (52%) 
no: 11 (48%) 
0.0001 
Physician in charge of the diagnosis of 
LM: neurologist 
(missing: 30) 
yes: 68 (88%) 
no: 9 (12%) 
yes: 15 (29%) 
no: 37 (71%) 
yes: 12 (28.5%) 
no 30 (71.5%) 
yes: 5 (21.5%) 
no: 18 (78%) 
<0.0001 
Physician in charge of the diagnosis of 
LM: radiotherapist 
(missing: 30) 
yes: 9 (11.5%) 
no: 68 (88%) 
yes: 9 (17.5%) 
no: 43 (82.5%) 
yes: 18 (43%) 
no: 24 (57%) 
yes: 10 (43.5%) 
no: 13 (56.5%) 
<0.0001 
Physician in charge of the diagnosis of 
LM: neurosurgeon 
(missing: 30) 
yes: 6 (8%) 
no: 71 (92%) 
yes:10 (19%) 
no: 42 (81%) 
yes: 7 (16.5%) 
no: 35 (83.5%) 
yes: 14 (61%) 
no: 9 (39%) 
<0.0001 
Physician in charge of the diagnosis of 
LM: other 
yes: 1 (1.50%) 
no: 76 (98.5%) 
yes: 5 (9.5%) 
no: 47 (90%) 
yes: 7 (16.5%) 
no: 35 (83.5%) 
yes: 3 (13%) 
no: 20 (87%) 
0.0215 
(missing: 30) 
Physician in charge of the treatment of 
LM: medical oncologist 
(missing: 30) 
yes: 47 (61%) 
no: 30 (39%) 
yes: 47 (90.5%) 
no: 5 (9.5%) 
yes: 25 (59.5%) 
no: 17 (40.5%) 
yes: 16 (69.5%) 
no: 7 (30.5%) 
0.0016 
Physician in charge of the treatment of 
LM: neurologist 
(missing: 30) 
yes: 57 (74%) 
no: 20 (26%) 
yes: 3 (6%) 
no: 49 (94%) 
yes: 5 (12%) 
no: 37 (88%) 
yes: 4 (17.5%) 
no: 19 (82.5%) 
<0.0001 
Physician in charge of the treatment of 
LM: radiotherapist 
(missing: 30) 
yes: 20 (26%) 
no: 57 (74%) 
yes: 12 (23%) 
no: 40 (77%) 
yes: 28 (67%) 
no: 14 (33.5%) 
yes: 9 (39%) 
no: 14 (61%) 
<0.0001 
Physician in charge of the treatment of 
LM: neurosurgeon 
(missing: 30) 
yes: 6 (8%) 
no: 71 (92%) 
yes: 2 (4%) 
no: 50 (96%) 
yes: 3 (7%) 
no: 39 (93%) 
yes: 11 (48%) 
no: 12 (52%) 
<0.0001 
Physician in charge of the treatment of 
LM: other 
(missing: 30) 
yes: 1 (1.5%) 
no: 76 (98.5%) 
yes: 4 (7.5%) 
no: 48 (92.5%) 
yes: 4 (7.5%) 
no: 38 (90.5%) 
yes: 0 (0%) 
no: 23 (100%) 
0.0928 
CSF analysis always performed in 
case of suspicion of LM from solid 
tumors (except glioma) 
(missing: 30) 
yes: 47 (61%) 
no: 30 (39%) 
yes: 41 (79%) 
no: 11 (21%) 
yes: 11 (26%) 
no: 31 (74%) 
yes: 14 (61%) 
no: 9 (39%) 
<0.0001 
CSF analysis always performed in 
case of suspicion of LM from glioma 
(missing: 30) 
yes: 13 (17%) 
no: 64 (83%) 
yes: 14 (23%) 
no: 38 (73%) 
yes: 2 (5%) 
no: 40 (95%) 
yes: 4 (17%) 
no: 19 (82.5%) 
0.0443 
CSF analysis performed in case of 
suspicion of LM from solid tumors 
(except glioma) in case of doubt after 
clinical and MRI evaluations  
(missing: 30) 
yes: 27 (35%) 
no: 50 (65%) 
yes: 11 (21%) 
no: 41 (79%) 
yes: 29 (69%) 
no: 13 (31%) 
yes: 7 (30.5%) 
no: 16 (69.5%) 
<0.0001 
CSF analysis performed in case of 
suspicion of LM from glioma in case of 
doubt after clinical and MRI 
evaluations  
(missing: 30) 
yes: 24 (31%) 
no: 53 (69%) 
yes: 3 (7%) 
no 49 (94%) 
yes: 7 (16.5%) 
no: 35 (83.5%) 
yes: 3 (13%) 
no: 20 (87%) 
0.0030 
CSF flow study always performed at 
LM diagnosis 
(missing:30) 
yes: 9 (11.5%) 
no: 68 (88%) 
yes: 13 (25%) 
no: 39 (75%) 
yes: 5 (12%) 
no 37 (88%) 
yes: 7 (30.5%) 
no: 16 (69.5%) 
0.0603 
Median volume of CSF sample 
(missing 42) 
>10 ml: 23 (31%) 
5-10 ml: 38 (51.5%) 
>10 ml: 9 (18%) 
5-10 ml: 17 (34%) 
>10 ml: 1 (3%) 
5-10 ml: 12 (54.5%) 
>10 ml: 1 (1.5%) 
5-10 ml: 0 (0%) 
0.0006 
2-5 ml: 12 (16%) 
0-2 ml: 1 (1.5%) 
2-5 ml: 24 (48%) 
0-2 ml: 0 (0%) 
2-5 ml: 6 (27.5%) 
0-2 ml: 2 (5.5%) 
2-5 ml: 2 (5.5%) 
0-2 ml: 0 (0%) 
Median time between CSF sampling 
and processing 
(missing:44) 
<30 min:  21 (29.5%) 
30-60 min: 27 (38%) 
60-90 min: 15 (21%) 
>90 min: 8 (11.5%) 
<30 min: 7 (14%) 
30-60 min: 29 (58%) 
60-90 min: 12 (24%) 
>90 min: 2 (4%) 
<30 min: 3 (8%) 
30-60 min: 18 (47.5%) 
60-90 min: 12 (31.5%) 
>90 min: 5 (13%) 
<30 min: 3 (14.5%) 
30-60 min: 18 (47.5%) 
60-90 min: 4 (19%) 
>90 min: 4 (19%) 
0.0847 
positive CSF cytology always required 
for LM diagnosis  
(missing: 37) 
yes: 6 (8%) 
no: 68 (92%) 
yes: 4 (8%) 
no: 47 (92%) 
yes: 5 ( 13%) 
no: 34 (87%) 
yes: 6 (26%) 
no: 17 ( 74%) 
0.0896 
Systemic treatment always 
administered for LM (when feasible) 
missing: 30 
yes: 17 (22%) 
no: 60 (73%) 
yes: 26 (50%) 
no: 26 (50%) 
yes: 11 (26%) 
no: 31 (74%) 
yes: 11 (48%) 
no: 12 (52%) 
0.0029 
Intra-CSF treatment always 
administered for LM 
(missing 30) 
yes: 6 (8%) 
no: 71 (92%) 
yes: 0 (0%) 
no: 52 (100%) 
yes: 0 (0%) 
no: 42 (100%) 
yes: 1 (4.5%) 
no: 22 (95.5%) 
0.0594 
Intra-CSF treatment depending on 
CSF and MRI characteristics 
(missing: 30) 
yes: 36 (47%) 
no: 41 (53%) 
yes: 22 (42%) 
no: 30 (57.5%) 
yes: 9 (21.5%) 
no:33 (78.5%) 
yes: 7 (30.5%) 
no: 16 (69.5%) 
0.0392 
Intra-CSF treatment administered 
depending on the primary cancer  
(missing: 30) 
yes: 51 (66%) 
no: 26 (34%) 
yes: 37 (71%) 
no: 15 (29%) 
yes: 23 (55%) 
no: 19 (45%) 
yes: 10 (43.5%) 
no: 13 (56.5%) 
0.0809 
Intra-CSF treatment administered only 
in combination with a systemic 
treatment 
(missing: 30) 
yes: 2 (2.5%) 
no: 75 (97.5%) 
yes: 3 (6%) 
no: 49 (94%) 
yes: 2 ( 5%) 
no: 40 (95%) 
yes: 4 (17.5%) 
no: 19 (82.5%) 
0.0620 
Intraventricular intra-CSF treatment is 
preferred on intralumbar intra-CSf 
treatment only if lumbar punctures are 
not feasible  
(missing: 30) 
yes: 40 (52%) 
no: 37 (48%) 
yes: 34 (65.5%) 
no: 18 (34.5%) 
yes: 16 (38%) 
no: 26 (62%) 
yes: 10 (43.5%) 
no: 13 (56.5%) 
0.0542 
WBRT always performed for LM 
treatment 
(missing: 30) 
yes:  11 (14.5%) 
no: 66 (86%) 
yes: 2 (4%) 
no: 50 (96%) 
yes: 12 (28.5%) 
no: 30 (71.5%) 
yes: 8 (35%) 
no: 15 (65%) 
0.0012 
WBRT performed in case of 
concomitant brain metastases 
(missing: 30) 
yes: 43 (56%) 
no: 34 (44%)  
yes: 32 (61.5%) 
no: 20 (38.5%) 
yes: 18 (43%) 
no: 24 (57%) 
yes: 8 (35%) 
no: 15 (65%) 
0.0901 
WBRT performed in case of multifocal 
nodular/bulky LM 
yes: 43 (56%) 
no: 34 (44%) 
yes: 38 (73%) 
no: 14 (27%) 
yes: 21 (50%) 
no: 21 (50%) 
yes: 9 (39%) 
no: 14 (61%) 
0.0248 
(missing 30) 
Focal RT based on neurological 
symptoms associated with MRI 
abnormalities only 
(missing: 30) 
yes: 55 (71.5%) 
no: 45 (86.5%) 
yes: 45 (86.5%) 
no: 7 (13.5%) 
yes: 38 (90.5%) 
no: 4 (9.5%) 
yes: 17 (74%) 
no: 6 (26%) 
 
0.0401 
Change of steroids dose part of criteria 
for LM response assessment  
(missing: 36) 
yes: 37 (50.5%) 
no: 36 (49.5%) 
yes: 42 (81%) 
no: 10 (19%) 
yes: 25 (62.5%) 
no: 15 (37.5%) 
yes: 13 (56.5%) 
no: 10 (43.5%) 
0.0071 
PHYSICIAN IN CHARGE OF LM IN THE CENTER VERSUS PHYSICIAN NOT IN CHARGE IN ITS CENTER 
 Participants declared as being the neuro-oncologist in 
charge (n=129) 
(n, % of participants) 
Participants declared as not being the neuro-oncologist in 
charge (n=74) 
(n, % of participants) 
 
Specialty of the participants 
(missing: 36) 
neurologist: 58 (47%) 
medical oncologist: 31 (25%) 
radiation oncologist: 23 (18.5%) 
neurosurgeon: 11 (9%) 
neurologist: 15 (23%) 
medical oncologist: 20 (31%) 
radiation oncologist: 19 (29%) 
neurosurgeon: 11 (17%) 
0.0104 
Physician in charge of the diagnosis of 
LM: medical oncologist 
(missing: 21) 
yes: 68 (52.5%) 
no: 61 (47.5%) 
yes: 51 (69%) 
no: 23 (31%) 
0.0240 
Physician in charge of the diagnosis of 
LM: neurologist 
(missing: 21) 
yes: 74 (57.5%) 
no: 55 (42.5%) 
yes: 31 (42%) 
no: 43 (58%) 
0.0337 
Physician in charge of the diagnosis of 
LM: neurosurgeon 
 (missing: 21) 
yes: 30 (23%) 
no: 99 (76.5%) 
yes: 10 (13.5%) 
no: 64 (86.5%) 
0.0930 
Physician in charge of the treatment of 
LM: medical oncologist 
(missing: 21) 
yes: 80 (62%) 
no: 49 (38%) 
yes: 58 (78.5%) 
no: 16 (21.5%) 
0.0162 
Physician in charge of the treatment of 
LM: neurologist 
(missing: 21) 
yes: 55 (42.5%) 
no: 74 (57.36) 
yes: 15 (20.5%) 
no: 59 (79.5%) 
0.0013 
Physician in charge of the treatment of 
LM: other 
(missing: 21) 
yes: 6 (4.5%) 
no: 123 (95.5%) 
yes: 8 (11%) 
no: 66 (89%) 
0.0955 
Standardized scale available 
(missing: 25) 
yes: 28 (21.5%) 
no: 101 (78.5%) 
yes: 8 (11.5%) 
no: 62 (88.5%) 
0.0721 
CSF flow study always performed at yes: 17 (13%) yes: 18 (24.5%) 0.0430 
LM diagnosis 
(missing: 21) 
no: 112 (87%) no: 56 (75.5%) 
Median CSF volume collected for CSF 
cytology at LM diagnosis  
(missing:31) 
>10 ml: 26 (20.5%) 
5-10 ml: 61 (48%) 
2-5 ml: 37 (29%) 
0-2 ml: 3 (2.5%) 
>10 ml: 13 (19.5%) 
5-10 ml: 23 (35%) 
2-5 ml: 30 (45.5%) 
0-2 ml: 0 (0%) 
0.0844 
A CSF cytology defined as suspicious 
is considered as 
(missing: 31) 
positive: 112 (89%) 
negative: 14 (11%) 
positive: 53 (79%) 
negative: 14 (21%) 
0.0661 
Intraventricular intra-CSF 
chemotherapy is preferred over 
intralumbar intra-CSF chemotherapy 
for most patients 
(missing: 21) 
yes: 40 (31%) 
no: 89 (69%) 
yes: 9 (12%) 
no: 65 (88%) 
0,0025 
Frequency of MRI examination during 
follow-up 
(missing: 28) 
every 2 months: 19 (14.5%) 
every 2 months initially, then every 3 months: 40 (31%) 
every 3 months: 37 (28.5%) 
only depending on the clinical course: 33 (25.5%) 
 
every 2 months: 10 (15%) 
every 2 months initially, then every 3 months: 13 (19.5%) 
every 3 months: 14 (21%) 
only depending on the clinical course: 30 (45%) 
 
0.0406 
PHYSICIAN IN CHARGE OF >2 LM PATIENTS PER MON TH VERSUS PHYSICIAN IN CHARGE OF 0-2 LM PATIENTS PER MONTH  
 At least 2 LM patients per month (n=88) 
(n, % of participants) 
0-1 LM patients per month (n=119) 
(n, % of participants) 
 
Physician in charge of LM patient at 
hospital 
(missing: 21) 
yes: 65 (75.5%) 
no: 21 (24.5%) 
yes: 64 (54.5%) 
no: 53 (45.5%) 
0.0023 
Physician in charge of LM treatment: 
medical oncologist 
(missing:18) 
yes: 53 (61%) 
no: 34 (39%) 
yes: 88 (74%) 
no: 31 (26%) 
0.0468 
Physician in charge of LM treatment: 
neurologist 
(missing:18) 
yes: 36 (41.5%) 
no: 51 (58.5%) 
yes: 35 (29.5%) 
no: 84 (70.5%) 
0.0742 
In case of negative CSF cytology, a 
combination of clinical and radiological 
signs is considered sufficient to 
diagnose LM 
(missing: 22) 
yes: 83 (97.5%) 
no: 2 (2.5%) 
yes: 108 (92.5%) 
no: 9 (7.5%) 
0.0987 
Intraventricular intra-CSF is preferred 
over intralumbar chemotherapy in most 
yes: 27 (31%) 
no: 60 (69%) 
yes: 23 (19.5%) 
no: 96 (80.5%) 
0.0529 
patients 
(missing: 18) 
Intraventricular intraCSF 
chemotherapy is preferred over 
intralumbar intraCSF if repeated 
lumbar punctures are not feasible 
(missing: 18) 
37 (42.5%) 
50 (57.5%) 
66 (55.5%) 
53 (44.4%) 
0.0667 
 
